Siraj Ali

Siraj Ali is a leading molecular oncologist who has been instrumental in the clinical development and FDA approval of Foundation Medicine's FoundationOne CDx as a companion diagnostic for multiple immunotherapy agents. His work validated TMB-H as a predictive biomarker for pembrolizumab in solid tumors, contributing to tumor-agnostic FDA approval. He has advanced the science of comprehensive genomic profiling to simultaneously assess multiple biomarkers including MSI, TMB, HRD, and PD-L1. His contributions have made precision genomic biomarker testing routine in oncology practice.